Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase 3 Randomized, Placebo-Controlled Trial

Summary

The Sorafenib HCC Assessment Randomized Protocol [SHARP] trial demonstrated that treatment with sorafenib prolonged overall survival by 44% and prolonged time to progression by 73% for patients with advanced hepatocellular carcinoma.

  • Gastrointestinal Cancers Clinical Trials
View Full Text